BMRN vs PROF · P/E 40, rev $2.85B vs rev $10.7M
Biomarin Pharmaceutical Inc (BMRN) versus Profound Medical Corp (PROF) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Profound Medical Corp (PROF) is a medical devices company listed on NASDAQ.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported PROF revenue for 2024-12-31 was $10.7M. Net income was -$27.8M. Revenue was up 48.4% from 2023-12-31 to 2024-12-31. PROF currently screens at market cap $238.7M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. PROF currently screens at market cap $238.7M.
Not investment advice. Open the BMRN and PROF stock pages for the full models.
Not investment advice.